title: Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
abstract: BACKGROUND
  The MEK inhibitor trametinib is currently undergoing clinical trials as the treatment of metastatic melanoma both alone and in combination with the BRAF inhibitor dabrafenib. One of the most frequent side-effects associated with its use as a single agent is the development of acneiform eruptions. These eruptions seem to be reduced when dosed in combination with dabrafenib.
  
  
  OBJECTIVE
  To investigate the prevalence of acneiform eruptions in patients taking the MEK inhibitor trametinib, both alone and in combination with dabrafenib.
  
  
  METHODS
  All patients enrolled in the trametinib alone (n = 13) or trametinib and dabrafenib combination (n = 30) clinical trials at a single site underwent a retrospective file review. The development and management of acne or acneiform eruptions was noted.
  
  
  RESULTS
  In total, 77% of the trametinib group developed an acneiform eruption on the trial, while only 10% developed acneiform lesions in the combination trial. The patients were treated with oral doxycycline, topical antibiotics or topical antiseptic washes, with a good response. However the condition recurred if these treatments were ceased and the patient was still on trametinib therapy.
  
  
  CONCLUSIONS
  The MEK inhibitor trametinib is associated with the development of acneiform eruptions. When combined with dabrafenib the frequency of this side-effect is reduced.
authors: Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
authors: Rachael
authors: R
authors: Anforth
authors: Michael
authors: M
authors: Liu
authors: Bao
authors: B
authors: Nguyen
authors: Pablo
authors: P
authors: Uribe
authors: Richard
authors: R
authors: Kefford
authors: Arthur
authors: A
authors: Clements
authors: Georgina V
authors: GV
authors: Long
authors: Pablo
authors: P
authors: Fernandez-Peñas
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy; D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002981:Clindamycin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004318:Doxycycline / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D010091:Oximes / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D014260:Triclosan / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; D002981:Clindamycin; D014260:Triclosan; D004318:Doxycycline; C561627:dabrafenib
keywords: BRAF inhibitor; MEK inhibitor; acneiform eruption; dabrafenib; melanoma; trametinib